Clinical Trials Logo

Pancreatic Carcinoma clinical trials

View clinical trials related to Pancreatic Carcinoma.

Filter by:

NCT ID: NCT06388967 Recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Detection Consortium

PCDC
Start date: March 15, 2023
Phase:
Study type: Observational

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

NCT ID: NCT06271291 Not yet recruiting - Clinical trials for Pancreatic Carcinoma

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Start date: May 1, 2024
Phase:
Study type: Observational

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

NCT ID: NCT06172478 Recruiting - Prostate Cancer Clinical Trials

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: February 26, 2024
Phase: Phase 2
Study type: Interventional

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.

NCT ID: NCT06168812 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.

NCT ID: NCT06115499 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Start date: December 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.

NCT ID: NCT06084013 Not yet recruiting - Clinical trials for Pancreatic Carcinoma

Use Of Indocyanine Green In Pancreas Surgery

Start date: March 2024
Phase:
Study type: Observational

This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.

NCT ID: NCT06080854 Not yet recruiting - Clinical trials for Pancreatic Carcinoma

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Start date: November 10, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.

NCT ID: NCT05830019 Recruiting - Clinical trials for Pancreatic Carcinoma

Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery

NCT ID: NCT05642962 Recruiting - Pancreatic Cancer Clinical Trials

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.

NCT ID: NCT05634564 Recruiting - Clinical trials for Pancreatic Carcinoma

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.